Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

BACKGROUND: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EBioMedicine
Glavni autori: Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7494676/
https://ncbi.nlm.nih.gov/pubmed/32927274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102990
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items